Paediatric Fungal infections

This section summarises published information regarding the concepts in managing invasive fungal infections in children, with specific reference to Aspergillus.

Broadly there are two sections comprising diagnosis and treatment regimes. The data here are sourced and summarised from a series of publications in Clinical Microbiology Infect. 16(9), 1319-53, 2010 by Groll et alWalsh et alDornbusch et al& all these references are more comprehensive than the data compiled here and we recommend referral to the original publications for further detail. 
To view any links to publication please register your name with the site here.

Children and in particular neonates and young infants, are a unique patient population, particularly with respect to fungal infections. 
Invasive fungal infections are dificult to diagnose - but response to treatment and outcome is dependent on a prompt initial diagnosis and the initiation of treatment.


Epidemiology and Clinical Trials

The epidemiology, presentation and pre-disposing conditions show significant differences in paediatric versus adult patients. 
The use of antifungal agents in this patient group requires an understanding of pharmacodynamics and safety issues - which accumulating evidence suggests can not always be empirically derived from data collected on usage in adult groups.


Many antifungal clinical trials have previously excluded paediatric groups so there is a lack of trials of large cohorts- but there is data in the literature for smaller cohorts of paediatric patients- for various antifungal treatments.
New antifungals are continually going into trials - however the need for evaluation in paediatric patients is great.


This website specialises in Aspergillus infections - but the lack of paediatric data has meant that we have included data for other types of fungal infections - where it may be useful. 

Collected articles on pediatric fungal infections (Searchable)

Computed content type (Paediatrics): 

Paediatrics

Pediatrics Fungal Infections

Displaying 11 - 20 of 203
Author year
Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, Henriet S, van der Sluis IM, Hanff LM, Warris A, Koch BCP, Brüggemann RJ. 2019
The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study. O'Reilly MA, Govender D, Kirkwood AA, Vora A, Samarasinghe S, Khwaja A, Grandage V, Rao A, Ancliff P, Pavasovic V, Cheng D, Carpenter B, Daw S, Hough R, O'Connor D. 2019
A pharmacokinetic model for voriconazole in a highly diversified population of children and adolescents with cancer. de Moraes Costa Carlesse FA, de Araujo OR, Marques LMA, da Silva DCB, Senerchia AA, Petrilli AS. 2019
Itraconazole induces regression of infantile hemangioma via down-regulation of the PDGF-D/PI3K/Akt/mTOR pathway. Chen S, Zhuang K, Sun K, Yang Q, Ran X, Xu X, Mu C, Zheng B, Lu Y, Zeng J, Dai Y, Sushmita P, Ran Y. 2019
Posaconazole in immunocompromised pediatric patients. Vicenzi EB, Cesaro S. 2019
Predictive ability of bedside nasal endoscopy to diagnose invasive fungal sinusitis in a pediatric population. Mulvey CL, Rizzi MD, Buzi A. 2019
The Role of Antifungals in Pediatric Critical Care Invasive Fungal Infections. Kaushik A, Kest H. 2019
Chronic granulamatous disease: two decades of experience from a pediatric immunology unit in a country with high rate of consangineous marriages. Kutukculer N, Aykut A, Karaca NE, Durmaz A, Aksu G, Genel F, Pariltay E, Cogulu Ö, Azarsız E. 2019
Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment Savvas Papachristou, Elias Iosifidis and Emmanuel Roilides 2019
Pediatric hyperimmunoglobulin E syndrome: A case series of 4 children in China. Fan H, Huang L, Yang D, Lin Y, Lu G, Xie Y, Yu J, Zhang D. 2018

Pages